Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.46 |
| ▸ | PGK1 | P00558 | 1/20 | 0.39 |
| ▸ | PGK2 | P07205 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26558208 | 0.91 | ADORA3 (0.61) | ADORA3ADORA1ADORA2BPGK1PGK2 | |
| SCHEMBL26326162 | 0.90 | ADORA3 (0.57) | ADORA3ADORA1ADORA2BPGK1PGK2 | |
| SCHEMBL24917056 | 0.86 | ADORA1 (0.47) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL16186319 | 0.85 | ADORA2A (0.43) | ADORA3ADORA1ADORA2A | |
| SCHEMBL14769912 | 0.85 | ADORA2A (0.43) | ADORA3ADORA1ADORA2A | |
| SCHEMBL17452103 | 0.85 | ADORA2A (0.43) | ADORA3ADORA1ADORA2A | |
| SCHEMBL18041228 | 0.84 | ADORA3 (0.65) | ADORA3ADORA1ADORA2BPGK1PGK2 | |
| SCHEMBL29363191 | 0.84 | ADORA3 (0.65) | ADORA3ADORA1ADORA2BPGK1PGK2 | |
| SCHEMBL25204813 | 0.84 | ADORA3 (0.65) | ADORA3ADORA1ADORA2BPGK1PGK2 | |
| SCHEMBL18061792 | 0.84 | ADORA3 (0.65) | ADORA3ADORA1ADORA2BPGK1PGK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238324-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11707480-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707480-B2 | Highly active compounds against COVID-19 | PNP, MTAP, ACE2 | ADORA3 98/4885ADORA1 116/4885ADORA2B 217/4885 |
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | NUDT1, PNP, ATIC | ADORA3 59/4885ADORA1 30/4885ADORA2B 80/4885 |
| US-20240238324-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | PNP, MTAP, ACE2 | ADORA3 98/4885ADORA1 116/4885ADORA2B 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.